Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin and amoxicillin. Staph infections, including MRSA, occur most frequently among persons in hospitals and healthcare facilities (such as nursing homes and dialysis centers) who have weakened immune systems.
MRSA infections that occur in otherwise healthy people who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-associated (CA)-MRSA infections. These infections are usually skin infections, such as abscesses, boils, and other pus-filled lesions.
An emerging form of so-called "flesh-eating bacteria" is caused by a strain that is resistant to standard first-line antibiotics. The same type of bacteria, methicillin-resistant Staphylococcus aureus (MRSA) is causing record numbers of less-serious skin infections in children and also is emerging as a cause of pneumonia, which can be deadly
Pine cones may form a new line of attack against methicillin-resistant Staphylococcus aureus (MRSA) infection, the British Pharmaceutical Conference heard this week.
Dangerous multi-drug-resistant bacteria are also developing immunity to hospital disinfectants and antiseptics, according to new research presented today at the Society for General Microbiology’s 155th Meeting at Trinity College Dublin.
Phico Therapeutics Ltd, a Cambridge-based company that has developed a unique anti-bacterial technology to treat the hospital superbug, MRSA, has raised £550,000 with the help of Oxfordshire Investment Opportunity Network, Europe’s leading technology business angel network.
The researchers stress that, although better studies are urgently needed, isolation measures should continue until further research establishes otherwise.
Staph bacteria are not uncommon in health care settings. In fact, they account for a large number of hospital-related infections each year.
Manchester Metropolitan University is working with a cutting edge technology firm to find a treatment for the hospital superbug MRSA which kills 5,000 patients each year.
Ring fencing of hospital wards and simple infection control measures can eradicate MRSA in patients having planned operations and allow more patients to be treated, show researchers in this week's BMJ.
The results from the third year of the mandatory surveillance scheme for Staphylococcus aureus show the number of blood-stream infections caused by both sensitive strains, and also strains resistant to methicillin (MRSA) broken down by regions and also by each acute NHS Trust.
Hospitals will have to display infection rates as part of a new drive to tackle superbugs like MRSA.
Methicillin resistant Staphylococcus aureus (MRSA) is a virulent organism, essentially resistant to all beta-lactam antibiotics (for example: penicillins, ampicillins, cephalosporins). It can cause skin, bone and life-threatening blood infections, as well as pneumonia.
On 18 June 2004, the BBC reported fears that deaths from the 'superbug' MRSA (methicillin-resistant Staphylococcus aureus) might double in the next five years.
Methicillin-resistant Staphylococcus aureus (MRSA) bacteria that are increasingly resistant to vancomycin, the antibiotic of last resort in the war against superbugs, have emerged independently in at least eight countries including the UK
Currently, attempts to prevent spread of these infections include isolating infected patients and increasing staff hygiene measures such as handwashing. However, these attempts have met with limited success.
Researchers had previously thought that such bacteria were emerging from only one sort of the MRSA superbug, but the new study has shown that they have evolved in all major types.
An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI).
MRSA is the first test to be developed from Acolyte’s BacLite® testing platform. BacLite reduces the time for identifying both the type of bacteria and, more importantly, the antibiotic sensitivity of the bacteria from the current 3-4 day standard to just 2-5 hours. This time advantage will mean clinicians will be able to treat, much more effectively, serious bacterial infections and prevent potentially fatal complications, such as sepsis and septic shock, from developing.